Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Trikafta elexacaftor / tezacaftor / ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation Reimburse with clinical criteria and/or conditions Complete
Bylvay odevixibat Progressive familial intrahepatic cholestasis (PFIC) Reimburse with clinical criteria and/or conditions Complete
Breztri Aerosphere budesonide/ glycopyrronium /formoterol fumarate chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete
Vitrakvi larotrectinib Solid tumours with NTRK gene fusion Reimburse with clinical criteria and/or conditions Complete
Tukysa tucatinib Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Tagrisso osimertinib Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Darzalex daratumumab Light chain (AL) amyloidosis Reimburse with clinical criteria and/or conditions Complete
Brukinsa zanubrutinib Waldenström’s macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
Waymade-Trientine trientine hydrochloride Wilson's Disease Reimburse with clinical criteria and/or conditions Complete
Adtralza tralokinumab atopic dermatitis Do not reimburse Complete